Author (year) | Drug | Number of patients | Response rate (%) |
---|---|---|---|
Taal (1993) [32] | MMC | 30 | 10 |
Patt (1996) [33] | 5FU | 32 | 34 |
Interferon alfa-2b | |||
Patt (2001) [34] | Cisplatin Interferon alpha-2b | 41 | 21 |
Doxorubicin | |||
5 FU | |||
Penz (2001) [35] | Gemcitabine | 32 | 22 |
Murad (2003) [36] | Gemcitabine | 26 | 31 |
5FU | |||
Kornek (2001) [37] | MMC/Capecitabine vs | 51 | 31 |
MMC/gemcitabine | 20 | ||
Ueno (2004) [38] | S1 | 19 | 21 |
Alberts (2005) [39] | Gem | 42 | 9.5 |
5FU | |||
Leucovorin | |||
Furuse (2006) [40] | Uracil-tegafur | 24 | 12.5 |
Doxorubicin | |||
Kim (2006) [41] | Gemcitabine | 29 | 34.5 |
Cisplatin | |||
Okusaka (2006) [42] | Gemcitabine | 40 | 17.5 |
Park (2006) [43] | Gemcitabine | 27 | 33.3 |
Cisplatin | |||
Hong (2007) [44] | Capecitabine | 32 | 40.6 |
Cisplatin | |||
Manzione (2007) [23] | Gemcitabine | 34 | 41 |
Oxaliplatin | |||
Furuse (2008) [45] | S1 | 40 | 35 |
Kim (2008) [46] | S1 | 51 | 30 |
Cisplatin | |||
Oh (2008) [27] | S1 | 15 | 6.7 |
Oxaliplatin | |||
Furuse (2009) [47] | Uracil-tegafur | 61 | 6.6 |
Doxorubicin | |||
Kim (2009) [25] | Gemcitabine | 40 | 15 |
Oxaliplatin | |||
Sasaki (2009) [48] | S1 | 28 | 34.3 |
Gemcitabine | |||
Gruenberger (2010) [30] | Cetuximab | 30 | 63 |
Gemcitabine | |||
Oxaliplatin | |||
Gunnlaugsson (2010) [22] | Capecitabine | 39 | 21 |
Oxaliplatin | |||
Kanai (2010) [49] | S1 | 25 | 30.4 |
Gemcitabine | |||
Karachaliou (2010) [24] | Irinotecan | 28 | 17.9 |
Oxaliplatin | |||
Chung (2011) [50] | Irinotecan | 39 | 20.5 |
Gemcitabine |